Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives.
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Arguably, the most notorious cause of HPPD is lysergic acid diethylamide (LSD), although the condition can also arise from substances such as mescaline, psilocybin, ibogaine, ayahuasca, ketamine, 3,4-methylenedioxymethamphetamine (MDMA or ecstasy), cannabis, and even alcohol.3–5”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An earlier review by Martinotti and colleagues3 was also based on 16 articles. The authors mentioned efficacy for an even wider range of pharmacological agents and recommended combining several different medications to treat HPPD and any underlying or new comorbid disorders.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pharmacological interventions are all experimental and practice-based.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Case reports and small-scale pharmacological studies show promising results with antipsychotics, antidepressants, antiepileptics, and benzodiazepines.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“The efficacy of these medications, however, remains unclear.3–5”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Thalamic Relay Functions and Their Role in Corticocortical Communication
Guillery, R. W., & Sherman, S. M. (2002) · Neuron · doi:10.1016/s0896-6273(01)00582-7 · Cited by 636
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Amanita muscaria: chemistry, biology, toxicology, and ethnomycology
Michelot, D., & Melendez-Howell, L. M. (2003) · Mycological Research · doi:10.1017/s0953756203007305 · Cited by 260 · cited 1×
“) [22]; San Pedro cactus and Peyote (mescaline) [16,23]; ketamine [24]; dextromethorphan [25]; MDMA and MDA [26]; and cannabis and synthetic cannabinoids [27–33].”
BackgroundCinosi, E., Martinotti, G., Simonato, P., Singh, D., Demetrovics, Z., Roman-Urrestarazu, A., Bersani, F. S., Vicknasingam, B., Piazzon, G., Li, J.-H., et al. (2015) · BioMed Research International · doi:10.1155/2015/968786 · Cited by 234 · cited 1×
“This is consistent with the rapid and vast diffusion of these novel psychoactive compounds, nowadays easily available without specific cultural filters and references [91,92].”
BackgroundSelf-citationCaton, C. L. M., Drake, R. E., Hasin, D. S., Dominguez, B., Shrout, P. E., Samet, S., & Schanzer, W. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.137 · Cited by 231 · cited 1×
“In fact, as in the vast majority of induced psychoses, visual hallucinations are notably more common than auditory [3].”
BackgroundHallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219 · cited 3×
“The main consideration that has to be done with respect to HPPD is its rare and unpredictable nature [16]: current prevalence estimates are unknown, but DSM-5 suggests 4.”
BackgroundClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · cited 2×
“The effectiveness of Benzodiazepines may be related to their activity on the cortical serotonergic-inhibitory inter-neurons with GABAergic outputs [2,4].”
BackgroundThe Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 173 · cited 2×
“In one study, haloperidol was noted to reduce hallucinations, but an exacerbation of flashbacks in the early phases of treatment was highlighted as well [1,69].”
BackgroundThe Relation Between Migraine, Typical Migraine Aura and “Visual Snow”
Schankin, C. J., Maniyar, F. H., Sprenger, T., Chou, D. E., Eller, M., & Goadsby, P. J. (2014) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12378 · Cited by 171 · cited 1×
“Recent research highlighted a brain dysfunction in patients with visual snow, located mainly in the right lingual gyrus [44], perhaps implying LSD involvement.”
BackgroundXu, X., Ichida, J. M., Allison, J. D., Boyd, J. D., Bonds, A. B., & Casagrande, V. A. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0203j.x · Cited by 161
Neural correlates of cognitive control in gambling disorder: a systematic review of fMRI studies
Moccia, L., Pettorruso, M., De Crescenzo, F., De Risio, L., di Nuzzo, L., Martinotti, G., Bifone, A., Janiri, L., & Di Nicola, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.025 · Cited by 158 · cited 1×
“Currently, brain stimulation treatments have been proposed as a possible therapeutic option to enhance the recovery of refractory symptoms in several disorders [82,83].”
BackgroundSelf-citationSanders-Bush, E., Burris, K. D., & Knoth, K. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22189-9 · Cited by 155
Adverse consequences of lysergic acid diethylamide
ABRAHAM, H. D., & ALDRIDGE, A. M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02018.x · Cited by 140 · cited 3×
“Prior substance users can voluntarily elicit or produce visual disturbances with or without known triggers [4,17,18].”
BackgroundLooking back: corticothalamic feedback and early visual processing
Cudeiro, J., & Sillito, A. M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.05.002 · Cited by 137
Halpern, J. H., Lerner, A. G., & Passie, T. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_457 · Cited by 133 · cited 3×
“Nonetheless, HPPD-like experiences, such as flashbacks, moments of derealization, and hyper-intense perceptions are reported in healthy populations and non-LSD exposed subjects [40].”
BackgroundInfluentialSelf-citationMartinotti, G., Lupi, M., Carlucci, L., Cinosi, E., Santacroce, R., Acciavatti, T., Chillemi, E., Bonifaci, L., Janiri, L., & Di Giannantonio, M. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2486 · Cited by 132
Self-citationNovel Psychoactive Substances in Young Adults with and without Psychiatric Comorbidities
Martinotti, G., Lupi, M., Acciavatti, T., Cinosi, E., Santacroce, R., Signorelli, M. S., Bandini, L., Lisi, G., Quattrone, D., Ciambrone, P., et al. (2014) · BioMed Research International · doi:10.1155/2014/815424 · Cited by 125 · cited 1×
“However, significant medical and psychiatric problems have been reported for subjects using these drugs [13], regardless of previous psychiatric antecedents [14].”
BackgroundSelf-citationTreatment of Aggressive Children with Clonidine: Results of an Open Pilot Study
Kemph, J. P., DeVane, C. L., Levin, G. M., JARECKE, R., & Miller, R. L. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199305000-00013 · Cited by 112 · cited 5×
“Symptoms alleviation has been reported in some patients treated with these drugs [17,18,52,63].”
BackgroundInfluentialBaggott, M. J., Coyle, J., Erowid, E., Erowid, F., & Robertson, L. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.006 · Cited by 99 · cited 3×
“The condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse [56], but it can arise in anyone, even after a single exposure (mostly to LSD, but it has also been reported after use of other psychedelics) [89].”
BackgroundMartinotti, G., Pettorruso, M., De Berardis, D., Varasano, P. A., Lucidi Pressanti, G., De Remigis, V., Valchera, A., Ricci, V., Di Nicola, M., Janiri, L., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw003 · Cited by 99 · cited 2×
“Agomelatine, given its peculiar function on neurotrophic factors [74], could have some benefits on the syndrome, although no data are available until now.”
BackgroundSelf-citationOrsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99
Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., Cinosi, E., Simonato, P., Martinotti, G., Bersani, G., et al. (2014) · BioMed Research International · doi:10.1155/2014/734749 · Cited by 97 · cited 1×
“However, significant medical and psychiatric problems have been reported for subjects using these drugs [13], regardless of previous psychiatric antecedents [14].”
BackgroundSelf-citationCorazza, O., Valeriani, G., Bersani, F. S., Corkery, J., Martinotti, G., Bersani, G., & Schifano, F. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.944291 · Cited by 83 · cited 1×
“Their use is becoming widespread, also due to their low cost and appealing market strategies [11,12].”
BackgroundSelf-citationSpagnolo, P. A., & Goldman, D. (2017) · Brain · doi:10.1093/brain/aww284 · Cited by 83 · cited 1×
“Currently, brain stimulation treatments have been proposed as a possible therapeutic option to enhance the recovery of refractory symptoms in several disorders [82,83].”
BackgroundLitjens, R. P. W., Brunt, T. M., Alderliefste, G. J., & Westerink, R. H. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.008 · Cited by 82 · cited 4×
“) [22]; San Pedro cactus and Peyote (mescaline) [16,23]; ketamine [24]; dextromethorphan [25]; MDMA and MDA [26]; and cannabis and synthetic cannabinoids [27–33].”
BackgroundInfluentialSchifano, F., Leoni, M., Martinotti, G., Rawaf, S., & Rovetto, F. (2003) · CyberPsychology & Behavior · doi:10.1089/109493103322278790 · Cited by 78 · cited 1×
“This is consistent with the rapid and vast diffusion of these novel psychoactive compounds, nowadays easily available without specific cultural filters and references [91,92].”
BackgroundSelf-citationEEG coherence in post-LSD visual hallucinations
Abraham, H. D., & Duffy, F. H. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00098-1 · Cited by 75 · cited 3×
“Investigations of HPPD patients with EEG mapping showed that HPPD is represented by disinhibition [35] in the cerebral cortex [34].”
BackgroundSchwitzer, T., Schwan, R., Angioï-Duprez, K., Ingster-Moati, I., Lalanne, L., Giersch, A., & Laprévote, V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.002 · Cited by 73
Martinotti, G., Nicola, M. D., Romanelli, R., Andreoli, S., Pozzi, G., Moroni, N., & Janiri, L. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.833 · Cited by 73
Self-citationHallucinogen-persisting perception disorder
Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312451270 · Cited by 72 · cited 2×
“In contrast with this supposition, Risperidone at recommended [71] and lower doses [72] worsens visual disturbances and accompanying anxiety, or does not show any effect [54].”
ResultMerabet, L. B., Kobayashi, M., Barton, J., & Pascual-Leone, A. (2003) · Neurocase · doi:10.1076/neur.9.5.436.16557 · Cited by 71 · cited 1×
“According to the cortical hyperexcitability hypothesis about its pathogenesis, several case reports propose that rTMS could be a promising therapeutic method for refractory visual hallucinations in schizophrenia [84,85].”
BackgroundOrsolini, L., Francesconi, G., Papanti, D., Giorgetti, A., & Schifano, F. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2466 · Cited by 70 · cited 1×
“Their use is becoming widespread, also due to their low cost and appealing market strategies [11,12].”
BackgroundNew trends in the cyber and street market of recreational drugs? The case of 2C-T-7 (‘Blue Mystic’)
Schifano, F., Deluca, P., Agosti, L., Martinotti, G., & Corkery, J. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056660 · Cited by 68
Self-citationLerner, A. G., Gelkopf, M., Skladman, I., Oyffe, I., Finkel, B., Sigal, M., & Weizman, A. (2002) · PubMed · Cited by 63
Self-citationJardri, R., Pins, D., Bubrovszky, M., Lucas, B., Thuc, V. L., Delmaire, C., Vantyghem, V., Despretz, P., & Thomas, P. (2009) · Consciousness and Cognition · doi:10.1016/j.concog.2008.12.009 · Cited by 62 · cited 1×
“Putative targets of stimulation could be hypothesized to be located in the visual cortical areas, as well as in the occipitotemporal sulcus [87].”
BackgroundHallucinogen persisting perception disorder after psilocybin consumption: a case study
Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.04.008 · Cited by 61 · cited 3×
“A vast list of psychoactive substances has been identified and linked with the development of this condition, including Magic Mushrooms (psilocybin) [21] and muscimol (Amanita muscaria (L.”
BackgroundLofexidine versus clonidine in rapid opiate detoxification
Gerra, G., Zaimovic, A., Giusti, F., Gennaro, C. D., Zambelli, U., Gardini, S., & Delsignore, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00178-7 · Cited by 57 · cited 3×
“8 mg/day) is a sympatholytic centrally acting α2 presynaptic adrenergic agonist that showed similar efficacy in some cases [23,65,66].”
BackgroundLerner, A. G., Gelkopf, M., Skladman, I., Rudinski, D., Nachshon, H., & Bleich, A. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200303000-00007 · Cited by 51
Self-citationGarratt, J. C., Alreja, M., & Aghajanian, G. K. (1993) · Synapse · doi:10.1002/syn.890130205 · Cited by 50
LSD-Like Panic From Risperidone in Post-LSD Visual Disorder
Abraham, H. D., & Mamen, A. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606000-00008 · Cited by 50 · cited 1×
“In contrast with this supposition, Risperidone at recommended [71] and lower doses [72] worsens visual disturbances and accompanying anxiety, or does not show any effect [54].”
ResultLow-Dose Topiramate in Alcohol Dependence: A Single-Blind, Placebo-Controlled Study
Martinotti, G., Di Nicola, M., De Vita, O., Hatzigiakoumis, D. S., Guglielmo, R., Santucci, B., Aliotta, F., Romanelli, R., Verrastro, V., Petruccelli, F., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000228 · Cited by 48
Self-citationMarkel, H., Lee, A., Holmes, R., & Domino, E. F. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(06)80189-7 · Cited by 47 · cited 1×
“There are questionable and controversial results regarding Sertraline, which has been reported to worsen [81] as well as to improve visual disturbances.”
ResultLauterbach, E., Abdelhamid, A., & Annandale, J. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-8452 · Cited by 44 · cited 8×
“Zobor, 2015 [29] 1 Cannabis Gaillard, 2003 [46] 2 Cannabis Lerner, 2014 [47] 2 Cannabis (Synthetic) Anderson, 2017 [48] 1 Cannabis and MDMA Stress Brodrick, 2016 [49] 1 Cannabis and LSD Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption Lerner, 2003 [51] 16 LSD Lerner, 2002 [20] 1 LSD Lerner, 2000…”
BackgroundInfluentialAbraham, H. D., & Duffy, F. H. (1996) · Psychiatry Research Neuroimaging · doi:10.1016/0925-4927(96)02833-8 · Cited by 44
Pregabalin in clinical psychiatry and addiction: pros and cons
Martinotti, G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703179 · Cited by 42
Self-citationMartinotti, G., Orsolini, L., Fornaro, M., Vecchiotti, R., De Berardis, D., Iasevoli, F., Torrens, M., & Di Giannantonio, M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1175431 · Cited by 42
Self-citationSide effects of dextromethorphan abuse, a case series
Ziaee, V., Hamed, E. A., ., A. H., Amini, H., Kebriaeizadeh, A., & Saman, K. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.02.005 · Cited by 39 · cited 1×
“) [22]; San Pedro cactus and Peyote (mescaline) [16,23]; ketamine [24]; dextromethorphan [25]; MDMA and MDA [26]; and cannabis and synthetic cannabinoids [27–33].”
BackgroundLerner, A. G., Gelkopf, M., Oyffe, I., Finkel, B., Katz, S., Sigal, M., & Weizman, A. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00005 · Cited by 39 · cited 7×
“Zobor, 2015 [29] 1 Cannabis Gaillard, 2003 [46] 2 Cannabis Lerner, 2014 [47] 2 Cannabis (Synthetic) Anderson, 2017 [48] 1 Cannabis and MDMA Stress Brodrick, 2016 [49] 1 Cannabis and LSD Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption Lerner, 2003 [51] 16 LSD Lerner, 2002 [20] 1 LSD Lerner, 2000…”
BackgroundInfluentialSelf-citation(2014) · PubMed · Cited by 39
Self-citationAllostasis as a Conceptual Framework Linking Bipolar Disorder and Addiction
Pettorruso, M., De Risio, L., Di Nicola, M., Martinotti, G., Conte, G., & Janiri, L. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00173 · Cited by 38
Self-citationUse of Haloperidol to Reduce LSD Flashbacks
Moskowitz, D. (1971) · Military Medicine · doi:10.1093/milmed/136.9.754 · Cited by 37 · cited 2×
“In one study, haloperidol was noted to reduce hallucinations, but an exacerbation of flashbacks in the early phases of treatment was highlighted as well [1,69].”
BackgroundExacerbation of hallucinogen-persisting perception disorder with risperidone.
Morehead, D. B. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00020 · Cited by 33 · cited 1×
“In contrast with this supposition, Risperidone at recommended [71] and lower doses [72] worsens visual disturbances and accompanying anxiety, or does not show any effect [54].”
ResultPersisting Visual Hallucinations and Illusions in Previously Drug-Addicted Patients
Gaillard, M.-C., & Borruat, F.-X. (2003) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-2003-38173 · Cited by 30 · cited 4×
“In a single case of HPPD symptoms and electroencephalographic (EEG) abnormalities, compatible with toxic encephalopathy, the visual hallucinations that recurred at any alcohol ingestion improved, but did not disappear with the use of Valproic Acid (1500 mg/day) [46].”
BackgroundInfluentialSertraline Treatment of Hallucinogen Persisting Perception Disorder
Young, C. R. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0206a · Cited by 29 · cited 1×
“This disinhibition may be linked to an LSD-generated intense current [37] that may determine the destruction or dysfunction [18] of cortical serotonergic inhibitory interneurons with gamma-Aminobutyric acid (GABAergic) outputs, implicated in sensory filtering mechanisms of unnecessary stimuli [34–36,38].”
BackgroundZobor, D., Straßer, T., Zobor, G., Schober, F., Messias, A. M. V., Strauß, O., Batra, A., & Zrenner, E. (2015) · Documenta Ophthalmologica · doi:10.1007/s10633-015-9481-2 · Cited by 28 · cited 3×
“The use of cannabis has been associated with the development of perceptual distortions in seven patients [29,46,48,49,61].”
BackgroundSantacroce, R., Corazza, O., Martinotti, G., Bersani, F. S., Valeriani, G., & Giannantonio, M. D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2410 · Cited by 25
Self-citationNaltrexone treatment of hallucinogen persisting perception disorder
Lerner, A. G., Oyefe, I., Isaacs, G., & Sigal, M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.3.437a · Cited by 25 · cited 3×
“25 mg of Clonidine three times a day for two months [59].”
BackgroundMethodSelf-citationHallucinogen persisting perception disorder in neuronal networks with adaptation
Kilpatrick, Z. P., & Ermentrout, B. (2011) · Journal of Computational Neuroscience · doi:10.1007/s10827-011-0335-y · Cited by 24 · cited 2×
“Interestingly, Kilpatrick and Ermentrout (2012) [86] studied the spatiotemporal dynamics of neuronal networks in HPPD, with spike frequency adaptation.”
BackgroundHallucinogen Persisting Perception Disorder and Risk of Suicide
Brodrick, J., & Mitchell, B. G. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190014566314 · Cited by 23 · cited 5×
“Zobor, 2015 [29] 1 Cannabis Gaillard, 2003 [46] 2 Cannabis Lerner, 2014 [47] 2 Cannabis (Synthetic) Anderson, 2017 [48] 1 Cannabis and MDMA Stress Brodrick, 2016 [49] 1 Cannabis and LSD Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption Lerner, 2003 [51] 16 LSD Lerner, 2002 [20] 1 LSD Lerner, 2000…”
BackgroundInfluentialKeaney, F., Strang, J., Gossop, M., Marshall, E. J., Farrell, M., Welch, S., Hahn, B., & Gonzalez, A. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.5.426 · Cited by 22 · cited 1×
“8 mg/day) is a sympatholytic centrally acting α2 presynaptic adrenergic agonist that showed similar efficacy in some cases [23,65,66].”
BackgroundLSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports.
Lerner, A., Skladman, I., Kodesh, A., Sigal, M., & Shufman, E. (2001) · PubMed · Cited by 21
Self-citationNew Drugs on the Internet: The Case of Camfetamine
Cinosi, E., Corazza, O., Santacroce, R., Lupi, M., Acciavatti, T., Martinotti, G., & Giannantonio, M. D. (2014) · BioMed Research International · doi:10.1155/2014/419026 · Cited by 21
Self-citationTrifluoperazine for The "Trailing" Phenomenon
O’Malley, J. E. (1972) · JAMA · doi:10.1001/jama.1972.03200090066017 · Cited by 19
Lerner, A. G., Goodman, C., Bor, O., & Lev‐Ran, S. (2014) · PubMed · Cited by 19
Self-citationLev‐Ran, S., Feingold, D., Frenkel, A., & Lerner, A. G. (2014) · Journal of Dual Diagnosis · doi:10.1080/15504263.2014.906155 · Cited by 18
Self-citationCoppola, M., & Mondola, R. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1316431 · Cited by 18 · cited 3×
“More recently, Clonazepam (6 mg/day) has been proved to be effective in improving cannabis-induced HPPD symptoms [50].”
BackgroundLerner, A. G., Goodman, C., Rudinski, D., & Bleich, A. (2011) · PubMed · Cited by 17
Self-citationLev‐Ran, S., Feingold, D., Goodman, C., & Lerner, A. G. (2017) · American Journal on Addictions · doi:10.1111/ajad.12577 · Cited by 17 · cited 2×
“Lev-Ran, 2017 [53] Observational cross-sectional study 40 (27 males); HPPD (DSM-IV-TR) Previous use of LSD; Lifetime use of Cannabis HPPD I: mean age 25.”
MethodSelf-citationUse of anti-epileptic medication in treating "flashbacks" from hallucinogenic drugs.
Thurlow, H. J., & Girvin, J. P. (1971) · PubMed Central · Cited by 16
Jolfaei, A. G., Naji, B., & Esfehani, M. N. (2016) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.17795/ijpbs-3561 · Cited by 15 · cited 1×
“According to the cortical hyperexcitability hypothesis about its pathogenesis, several case reports propose that rTMS could be a promising therapeutic method for refractory visual hallucinations in schizophrenia [84,85].”
BackgroundLerner, A. G., & Lev‐Ran, S. (2015) · PubMed · Cited by 14
Self-citationLerner, A. G., Shufman, E., Kodesh, A., Kretzmer, G., & Sigal, M. (2002) · PubMed · Cited by 13
Self-citation(2014) · PubMed · Cited by 13
Self-citationNovel psychoactive substances and induced phenomena in psychopathology: The lysergic psychoma
Martinotti, G., Nicola, M. D., Quattrone, D., Santacroce, R., Schifano, F., Murray, R. M., & Giannantonio, M. D. (2015) · Research Portal (King's College London) · Cited by 13
Self-citationThe trip of a lifetime: hallucinogen persisting perceptual disorder
Anderson, L., Lake, H., & Walterfang, M. (2018) · Australasian Psychiatry · doi:10.1177/1039856217726694 · Cited by 13 · cited 6×
“Zobor, 2015 [29] 1 Cannabis Gaillard, 2003 [46] 2 Cannabis Lerner, 2014 [47] 2 Cannabis (Synthetic) Anderson, 2017 [48] 1 Cannabis and MDMA Stress Brodrick, 2016 [49] 1 Cannabis and LSD Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption Lerner, 2003 [51] 16 LSD Lerner, 2002 [20] 1 LSD Lerner, 2000…”
BackgroundInfluentialSchizophrenia and hallucinogen persisting perception disorder: A clinical investigation
Lev‐Ran, S., Feingold, D., Rudinski, D., Katz, S., & Lerner, A. G. (2015) · American Journal on Addictions · doi:10.1111/ajad.12204 · Cited by 12 · cited 6×
“Zobor, 2015 [29] 1 Cannabis Gaillard, 2003 [46] 2 Cannabis Lerner, 2014 [47] 2 Cannabis (Synthetic) Anderson, 2017 [48] 1 Cannabis and MDMA Stress Brodrick, 2016 [49] 1 Cannabis and LSD Coppola, 2017 [50] 1 Cannabis (Synthetic, JWH-122) Cannabis consumption Lerner, 2003 [51] 16 LSD Lerner, 2002 [20] 1 LSD Lerner, 2000…”
BackgroundMethodInfluentialSelf-citationAlcántara, A. G. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00016 · Cited by 9
Vroegop, M. P., van Dongen, R. T. M., Vantroyen, B., & Kramers, C. (2007) · PubMed · Cited by 8
Markel, H., Lee, A., Holmes, R., et al. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70083-4 · Cited by 8
A persisting perception disorder after cannabis use
Ellison‐Wright, Z., & Sessa, B. (2015) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.363 · Cited by 7
1589 Levetiracetam efficacy in hallucinogen persisting perception disorders: a prospective study
(2005) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(05)81946-x · Cited by 5 · cited 1×
“Levetiracetam has shown to reduce some visual symptoms as well as HPPD related-depersonalization and derealization [80].”
Research works printed but not linked: 8
- Hofmann A. LSD: My Problem Child McGraw-Hill New York, NY, USA 1980
- Lerner A.G. Flashbacks and Hppd (Hallucinogenic Persisting Perception Disorder): Clinical Aspects and Pharmacological Treatment Proceedings of the First World Congress of the World Association on Dual Disorders Madrid, Spain 23–26 March 2017
- Stahl S.M. Stahl’s Essential Psychopharmacology 1st ed. Cambridge University Press New York, NY, USA 1996
- Goodman C. Bor O. Lev-Ran S. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two case reports Isr. J. Psychiatry Relat. Sci. 2014 51 277 280 25841224
- Kolb L. Burris B.C. Griffitshs S. Propanolol and Clonidine in the Treatment of Post Traumatic Disorders of War van der Kolk B.A. Post Traumatic Stress Disorder: Psychological and Biological Sequelae American Psychiatric Press Washington, DC, USA 1984
- Noushad F. Al Hillawi Q. Siram V. Arif M. 25 years of Hallucinogen Persisting Perception Disorder—A diagnostic challenge Br. J. Med. Pract. 2015 8 a805
- Aicardi J. Epilepsy: A Comprehensive Textbook 2nd ed. Wolters Kluwer Health/Lippincott Williams & Wilkins Philadelphia, PA, USA 2008
- Martinotti G. Ferro F. The exogenous model of induced psychotic experience in addiction Res. Adv. Psychiatry 2015 2 81 82
Cited by
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 135
“Given the historic spotlighting of enduring psychotic symptoms 52,53 and HPPD 54 after psychedelic-use, we felt particularly motivated to discover cases of these phenomena in the present study.”
BackgroundVisual snow syndrome: A clinical and phenotypical description of 1,100 cases
Puledda, F., Schankin, C. J., & Goadsby, P. J. (2020) · Neurology · doi:10.1212/wnl.0000000000008909 · Cited by 124
“Sudden onset of symptoms, n/N (%) 176/691 (26) 4/16 (25) 38/47 (81)”
Metadata
- Authors
- Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A.
- Affiliations
- University of Hertfordshire (GB)
- Università Cattolica del Sacro Cuore (IT)
- University of Chieti-Pescara (IT)
- Department of Neuroscience, Imaging and Clinical Sciences, University “G. d’Annunzio”, 66100 Chieti, Italy
- Tel Aviv University (IL)
- Corresponding author
- Santacroce, Rita
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-16
- Volume
- 8
- Issue
- 3
- Pages
- 47
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC5870365
- OpenAlex
- W2790481213
- Cited by
- 171
- References
- 84
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 24 · 2023: 22 · 2022: 24 · 2021: 26 · 2020: 33 · 2019: 8 · 2018: 6
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- hallucinogen persisting perception disorder, HPPD, hallucinogens, psychedelics, etiology, clinical features, psychiatric comorbidity, substance abuse, treatment options
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
